DIRS.INFO The most relevant business & tech news

☆ Bausch + Lomb CEO Brent Saunders goes one-on-one with Jim Cramer
▼ + stars: | 2024-02-21 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Bausch + Lomb Chairman and CEO Brent Saunders joins 'Mad Money' host Jim Cramer to talk earnings. Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email

Persons: Bausch, Brent Saunders, Jim Cramer

☆ Jim Cramer says buy this data center equipment firm despite its weak guidance
▼ + stars: | 2024-02-21 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +1 min

Vertiv Holdings : The data center equipment maker, whose shares have roughly quadrupled over the past year, issued guidance that didn't live up to Wall Street's lofty expectations. "Data center still strong. Teladoc Health : Shares tumbled 24% after the telehealth provider's quarterly revenue missed estimates and offered soft guidance. Bausch + Lomb : Shares jumped more than 8% after the Canadian eye-care company delivered a better-than-expected quarter alongside an upbeat sales forecast. SolarEdge Technologies : While the solar company's quarterly loss was smaller than anticipated, its current quarter guidance was weak, sending the stock sliding more than 15%.

Persons: Jim Cramer, Jim, Bausch, they've, Brent Saunders, SolarEdge Organizations: Vertiv Holdings, Teladoc, SolarEdge Technologies

☆ Bausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach Home
▼ + stars: | 2023-11-28 | by ( E.B. Solomont | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/real-estate/luxury-homes/bausch-lomb-ceobrent-saunders-pays-35-35-million-for-chers-former-miami-beach-home-fa6d279e

Persons: Dow Jones, saunders Locations: miami

☆ Bausch + Lomb to buy Novartis dry-eye drug for $1.75 bln
▼ + stars: | 2023-06-30 | by ( ) www.reuters.com time to read: 1 min

June 30 (Reuters) - Bausch + Lomb Corp (BLCO.TO) will purchase a dry-eye drug from Swiss pharma company Novartis (NOVN.S) for $1.75 billion, the companies said on Friday, as the contact lens maker seeks to capitalise on a growing market for the disease's treatment. Acquisition of the drug, Xiidra, will mark the first big deal by CEO Brent Saunders since he returned to the company in March. Sales of the anti-inflammation eye drop Xiidra, mainly from the U.S. market, were $487 million last year, up 4%. The deal will also include potential milestone payments worth up to $750 million. Reporting by Leroy Leo in Bengaluru and Ludwig Burger in Frankfurt; Editing by Anil D'Silva and Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

Persons: Brent Saunders, Leroy Leo, Ludwig Burger, Anil D'Silva, Vinay Dwivedi Organizations: Lomb, Swiss pharma, Novartis, Thomson Locations: U.S, Bengaluru, Frankfurt

☆ Top things to watch in the stock market Friday ahead of July 4 week
▼ + stars: | 2023-06-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Citi initiates coverage with a buy rating and a $240-per-share price target, which puts the stock at 30 times fiscal year 2025 earnings-per-share (EPS) estimates. Jefferies upgrades Carnival (CCL) to a buy rating and increases its price target to $25 per share from $9. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Dow, it's, Bausch, Brent Saunders, Morgan Stanley, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Dow, Apple, Citi, Nike, JPMorgan, Nice, Modelo, Constellation Brands, Jefferies, Novartis, Troubled, Bausch Health, Mastercard, Jim Cramer's Charitable, CNBC Locations: Corona

☆ 'I don't think we ever go back to where we were' with in-office work: Bausch + Lomb CEO Saunders
▼ + stars: | 2023-06-12 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'I don't think we ever go back to where we were' with in-office work: Bausch + Lomb CEO SaundersBrent Saunders, Bausch + Lomb CEO and Roam board chair, joins 'Squawk Box' to discuss the future of work, why remote work is here to stay, and more.

Persons: Saunders Brent Saunders, Bausch

☆ Jim Cramer talks to Bausch + Lomb CEO Brent Saunders on returning to the company
▼ + stars: | 2023-05-03 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Jim Cramer talks to Bausch + Lomb CEO Brent Saunders on returning to the companyBausch + Lomb CEO Brent Saunders joins 'Mad Money' host Jim Cramer on returning to the company as CEO, the company's quarterly results, and its forward looking strategy.

☆ Here’s our Annual Meeting update on the 7 health care and bank stocks in the Club portfolio
▼ + stars: | 2023-03-01 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Here's an update on the health care and financial holdings in Jim Cramer's Charitable Trust, the portfolio we use at the CNBC Investing Club. At levels below $250 per share, Jim said Danaher is one of the most attractive stocks in the Club's portfolio. Its consumer-products unit will become a company known as Kenvue, while its faster-growing pharmaceutical and medical devices divisions will retain the J & J name. However, there is some litigation risk with J & J after a federal judge in January rejected its strategy concerning more than 38,000 talc lawsuits. Against that backdrop, we view J & J as a quality defensive name to own, especially given its annual dividend yield of around 3%.

Generative AI boost for Nvidia NVDA 1Y mountain Nvidia (NVDA) 1-year performance Nvidia (NVDA) was the Club's biggest winner in January, climbing 33.7%, and in February its 18.8% monthly gain is second to only Bausch Health (BHC). The stock's exceptional performance this year goes much deeper to company-specific factors — specifically, all the buzz around generative artificial intelligence (AI). "AI adoption is at an inflection point," Nvidia CEO Jensen Huang said on the chipmaker's earnings conference call last week. Bausch bounces, but questions remain BHC 1Y mountain Bausch Health (BHC) 1-year performance Bausch Health (BHC) has had an incredible start to the year, climbing roughly 21% in both January and February. Efficiency commitment lifts Meta META 1Y mountain Meta Platform (META) 1-year performance Meta Platforms (META) has really turned it around, gaining roughly 24% in January and over 17% in February.

☆ Returning pharma CEO has one prescription: M&A
▼ + stars: | 2023-02-17 | by ( Robert Cyran | ) www.reuters.com time to read: +3 min

NEW YORK, Feb 17 (Reuters Breakingviews) - Brent Saunders is back in charge of a pharmaceutical company, which usually means one thing: M&A. The buyer, Actavis, appointed Saunders CEO of the combined company. Bausch + Lomb remains a subsidiary of Bausch Health, which owns nearly 90% of the shares. Considering Bausch Health’s stake in Bausch + Lomb is worth more than $5 billion, the implication is that bondholders are in charge. Saunders was CEO of Bausch + Lomb from 2010 until 2013, when it was acquired by Valeant Pharmaceuticals.

☆ Why energy and tech stocks are struggling Friday — listen to the 'Homestretch'
▼ + stars: | 2023-02-17 | by ( ) www.cnbc.com time to read: +7 min

YOU KNOW, WE'VE HAD A NICE RUN. THAT'S WHY WHEN YOU SEE INTERESTRATES RISE, STOCKS TEND TO FALL. NOW, ON THE OTHER HAND, NOTWORKING, THAT'S GOING TO BEENERGY WITH OIL PRICES FALLINGAND NAT GAS MAKING A NEW LOW. THEN, OF COURSE, TECH ISFALLING, AS WELL, BECAUSE ASINTEREST RATES RISE, TECH STOCKSTEND TO FALL. A LOT OF THESE TECH STOCKS, ALOT OF THEM HAVE EARNINGS --MANY ARE NOT PROFITABLE TODAYAND EARNINGS ARE PROMISED IN THEFUTURE.

☆ Eye-Care Company Bausch + Lomb to Name Brent Saunders CEO
▼ + stars: | 2023-02-15 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

Brent Saunders is expected to serve in his second stint as the head of Bausch + Lomb. Eye-care company Bausch + Lomb Corp. is expected to name Brent Saunders as chief executive officer and chairman of its board, according to people familiar with the matter. Mr. Saunders would succeed Joseph Papa , who had said last July that he would step down from his roles running the company and serving on its board. The leadership change could be announced as soon as Wednesday, the people said.

☆ Eye-Care Company Bausch + Lomb Names Brent Saunders CEO
▼ + stars: | 2023-02-15 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/eye-care-company-bausch-lomb-to-name-brent-saunders-ceo-e7eb0876

☆ Buyers swoop in to help the S&P 500 shake off earlier losses — listen to the 'Homestretch'
▼ + stars: | 2023-02-15 | by ( ) www.cnbc.com time to read: +17 min

I LIKE A STOCK THAT'S DE-RISKEDWHICH IS WHY I THINK EMERSON ISA GREAT BUY. I THINK THAT'S A GOOD STRATEGY. JEFF, I DON'T KNOW HOW ELSE TOPUT IT. I DON'T THINK ANYONE SHOULD SELLTHIS ON THE NOTION THAT THERE'SAN ANALYST WHO MISSED THE WHOLETHING IS SAYING SELLING. >> THAT'S GREAT.

☆ Jim Cramer's Investing Club meeting Wednesday: Retail sales, Devon, Bausch Health
▼ + stars: | 2023-02-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Watch Bausch A welcome leadership change at eye-care firm Bausch + Lomb (BLCO) is causing shares of Club holding Bausch Health (BHC) to surge 13% Wednesday, to roughly $8.52 apiece. Bausch Health owns nearly 89% of Bausch + Lomb, so what's good news at BLCO is good news for BHC, too. Saunders is a solid pick to lead Bausch + Lomb, which had been a division of Bausch Health up until May 2022. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Top 10 things the Club is watching in the stock market Wednesday: Retail sales up, stocks dip, Airbnb soars
▼ + stars: | 2023-02-15 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Retail sales for January came in higher than expected. Remember, retail sales are not adjusted for inflation, which of course remains elevated but growing at a slower rate in recent months. Earnings per share (EPS) of 48 cents versus 25 cents expected. Kraft Heinz (KHC) EPS beats: 85 cents versus 78 cents expected. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ The House That Botox Built: Ex-Allergan CEO Lists Miami Home for $21.9 Million
▼ + stars: | 2022-09-19 | by ( E.B. Solomont | ) www.wsj.com time to read: 1 min

Be the first to know about the biggest and best luxury home sales and listings by signing up for our Mansion Deals email alert. Brent Saunders , former CEO of the Botox maker Allergan, is listing his contemporary Miami home for $21.9 million.

Search resuls for: "Brent Saunders"

17 mentions found